|Year : 2011 | Volume
| Issue : 1 | Page : 60-67
Role of RT-PCR and FISH in diagnosis and monitoring of acute promyelocytic leukemia
S Polampalli1, A Choughule2, K Prabhash1, P Amare3, C Baisane3, S Kabre3, S Mahadik4, S Shinde4, R Nair1, S Banavali1
1 Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
2 Department of Medical Oncology and Hematopathology, Tata Memorial Hospital, Mumbai, India
3 Department of Cancer Cytogenetics, Tata Memorial Hospital, Mumbai, India
4 Department of Hematopathology, Tata Memorial Hospital, Mumbai, India
|Date of Web Publication||10-Feb-2011|
Department of Medical Oncology, Tata Memorial Hospital, Mumbai
Source of Support: None, Conflict of Interest: None
Background: Patients with a presence of Promyelocytic Leukemia-Retinoic Acid Receptor Alpha (PML-RARA) genes rearrangement predict a favorable response to all-trans retinoic acid (ATRA), and a significant improvement in survival. Therefore, establishing the presence of PML-RARA rearrangement is important for optimal patient management. Aim: The objective of this study is to compare and assess the role of fluorescent in situ hybridization (FISH) and reverse transcriptase polymerase chain reaction (RT-PCR) in the diagnosis and long-term monitoring of Acute Promyelocytic Leukemia (APL). Materials and Methods: We compared 145 samples received at different interval of times to analyze the sensitivity of RT-PCR and FISH. Results: The failure rate for RT-PCR was 4% at baseline, 13% at induction, and 0% at the end of consolidation. And for FISH it was 8% at baseline, 38% at induction, and 66% at the end of consolidation. The predictive values of relapse in the patients who were positive and negative by RT-PCR, at the end of induction, were 60 % and 3%, respectively, and at end of consolidation it was 67 % and 4%, respectively. On the other hand the predictive values of relapse in patients who were positive and negative by FISH at end of induction were 57 % and 6%, respectively; while at end of consolidation it was 14% who were negative by FISH. Conclusion: Both RT-PCR and FISH are important for the diagnosis of APL cases, as both techniques complement each other in the absence or failure of any one of them. However, RT-PCR is more sensitive than FISH for the detection of minimal residual disease in the long-term monitoring of these patients. The present study shows that the predictive value of relapse is more associated with minimal residual disease (MRD) results by RT-PCR than that by FISH.
Keywords: Reverse transcriptase polymerase chain reaction, fluorescent in situ hybridization, acute promyelocytic leukemia
|How to cite this article:|
Polampalli S, Choughule A, Prabhash K, Amare P, Baisane C, Kabre S, Mahadik S, Shinde S, Nair R, Banavali S. Role of RT-PCR and FISH in diagnosis and monitoring of acute promyelocytic leukemia. Indian J Cancer 2011;48:60-7
|How to cite this URL:|
Polampalli S, Choughule A, Prabhash K, Amare P, Baisane C, Kabre S, Mahadik S, Shinde S, Nair R, Banavali S. Role of RT-PCR and FISH in diagnosis and monitoring of acute promyelocytic leukemia. Indian J Cancer [serial online] 2011 [cited 2021 Jun 12];48:60-7. Available from: https://www.indianjcancer.com/text.asp?2011/48/1/60/75831
| » Introduction|| |
Acute promyelocytic leukemia (APL) is characterized by the reciprocal translocation t(15;17)(q22;q21) leading to the formation of PML-RARA and RARA-PML fusion genes. , PML-RARA is believed to be critical for leukemogenesis. , In patients with morphological APL the presence of a PML-RARA rearrangement predicts a favorable response to retinoids such as ATRA,  which, in combination with chemotherapy, has been found to provide significant improvement in survival.  Therefore, establishing the presence of a PML-RARA rearrangement in suspected APL cases is valuable for optimal patient management, and for the analysis of clinical trials. Generally, conventional karyotyping (CK), fluorescence in situ hybridization (FISH), and reverse transcriptase-polymerase chain reaction (RT-PCR) are the techniques used for detecting this abnormality. Early studies in specialized centers suggested that t(15;17) can be detected by cytogenetics in virtually all cases of morphological APL.  CK has been a gold standard for the detection of unique translocation markers and additional chromosomal aberrations such as trisomy and tetrasomy 8, iso 17q, and other variant translocations such as t(15;19;17). ,, However, large multi-center clinical trials, such as the MRC ATRA trial, have demonstrated that t(15;17) is not detected by cytogenetics in at least 10% of the cases in which PML-RARA rearrangements are demonstrated by molecular methods such as FISH and RT-PCR. , In recent studies, FISH on metaphases and interphases from cytogenetic preparations has been shown to be a useful tool in identifying PML-RARA in APL patients at the time of diagnosis and for minimal residual disease. , The RT-PCR status after completion of therapy is of prognostic significance and emphasizes the importance of the achievement of molecular remission as a prerequisite for long-term survival. RT-PCR allows the identification of one abnormal cell out of 10 4 -10 6 . , FISH on the other hand has a detection limit of 10 -3 in treated patients.  Most of these studies are individual studies, either focusing on RT-PCR or FISH. However, there have not been many studies, except for few,  where both these techniques were compared together, in order to find the advantages and limitations of one technique in comparison to another technique.
The objective of this study was to compare and assess the role of FISH and RT-PCR in the diagnosis and long-term monitoring of APL.
| » Materials and Methods|| |
We compared 52 diagnostic samples received for RT-PCR and FISH at baseline during the period 2006 - 2008. We also compared the follow-up samples received for RT-PCR and FISH, for minimal residual monitoring after initiation of therapy, at different interval of times, to analyze the sensitivity of both the techniques. The protocols used for both the techniques were as follows;
Reverse transcriptase-polymerase chain reaction
Total RNA was extracted from the bone marrow samples using the standard techniques. cDNA was prepared by using the commercially available kit (Fermentas), using Random Hexamer primer. To develop the sensitivity and specificity for PML-RARA, HOT start RT-PCR was performed,  using a specific primer for PML-RARA, with forward primer: 5'ACC GAT GGC TTC GAC GAG TTC3'; and reverse primer: 5'AGC CCT TGC AGC CCT CAC AG 3'. PCR conditions were as follows: Initial denaturation at 95oC for 15 minutes, followed by five cycles, each consisting of denaturation at 96oC for one minute, annealing at 55oC for 15 minutes, extension at 72oC for two minutes, and final extension at 72oC for two minutes. This was followed by 30 cycles, each consisting of denaturation at 94oC for 35 seconds, annealing at 55oC for one minute, extension at 72oC for three minutes, and final extension at 72oC for 10 minutes. Final cooling was at 4oC. The PCR product was electrophoresed on 2% agarose gel and the band was analyzed. The long (L) form showed three bands at 291, 550, and 691 base pairs; while the short (S) form showed a single band at the 220 base pair [Figure 1]. With each batch of samples, positive and negative controls were run. For internal controls, β-actin mRNA was used.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was carried out using the direct fluorescence method, on fixed cytogenetic specimens of bone marrow aspirate samples as per protocols supplied by Vysis Inc / Oncor, with some modifications. , After dehydrating the slides in ethanol grades (70, 85, and 100%), slides were co-denatured along with a FISH probe on a Hybrite machine for five minutes at 73ºC, followed by overnight hybridization at 37ºC. Stringent washes of the slides were done in 0.4XSSCN (NP 40 - 0.3%) at 73 ° C for two minutes followed by 2XSSCN (NP 40 - 0.1%) at room temperature for one minute. DAPI / Antifade was applied and signals were observed under an epifluorescent microscope. FISH studies were performed using the LSI dual fusion dual color probe for PML and RARa (D-FISH) (Abott Molecular-Vysis, Des Plaines, IL; Delkenheim, Germany), which allows identification of reciprocal PML-RARA and RARA-PML and also additional aberrations. The RARA break-apart probe (Abott Molecular-Vysis, Des Plaines, IL; Delkenheim, Germany) was used to increase the diagnostic sensitivity, which could simultaneously detect variant translocations such as t(11;17) and t(5;17), along with t(15,17). Two hundred interphases cells were counted by two observers. The cut-off value was taken as 10% by simultaneously studying the normal samples. Positive and negative controls were used with each batch.
| » Results|| |
Out of 52 baseline samples which were diagnosed as APL, 50 samples were diagnosed by RT-PCR and 48 samples by FISH [Table 1].
|Table 1 :Results of transcriptase polymerase chain reaction and fluorescent in situ hybridization in baseline samples |
Click here to view
Out of a total of six negative samples, four samples were positive by RT-PCR and two positive by FISH, with failure rate for RT-PCR being 4% and that for FISH being 8%.
Two samples had very faint RNA, which led to false negative results by RT-PCR.
Minimal residual disease monitoring
After initiation of treatment with all-trans retinoic acid (ATRA) along with chemotherapy, the samples were sent for RT-PCR and FISH studies for minimal residual monitoring at the end of induction, at the end of consolidation, and at different intervals of maintenance therapy. We analyzed these samples to assess the sensitivity of both the techniques at the end of induction, consolidation, and maintenance.
Samples analyzed at the end of induction
Forty-two samples were received for RT-PCR monitoring of minimal residual disease monitoring at the end of induction. These samples were compared with the FISH results to assess the sensitivity of both the techniques. Out of the 42 samples, two samples did not have any RNA, and therefore, were not processed further. However, these two samples were negative by FISH. The remaining 40 samples were compared by both the techniques as shown in [Table 2].
|Table 2 :Transcriptase polymerase chain reaction and fluorescent in situ hybridization comparison at end of induction |
Click here to view
Out of the 40 samples, eight samples (20%) showed the presence of PML-RARA by RT-PCR and / or FISH. Discordance between RT-PCR and FISH was seen in four samples. Out of these four samples, one sample was negative by RT-PCR, but positive by FISH, with a failure rate of 13% (failed to detect PML-RARA in one out of eight positive samples). Although, on the other hand, three samples were negative by FISH, but positive by RT-PCR, with a failure rate of 38% (failed to detect PML-RARA in three out of eight positive samples).
Samples analyzed at the end of consolidation (Second follow-up)
Twenty-six samples were analyzed at the end of consolidation by RT-PCR and FISH. Out of these 26 samples, three samples (12%) were positive by RT-PCR and / or FISH [Table 3]. Discordance was seen in two samples, which were positive by RT-PCR, but negative by FISH, with the failure rate for FISH being 66% (failed to detect PML-RARA in two out of three positive samples).
|Table 3 :Transcriptase polymerase chain reaction and fluorescent in situ hybridization comparison at end of consolidation |
Click here to view
Out of these three cases, two cases were positive by RT-PCR, but negative by FISH in the previous follow-up sample, that is, at the end of induction, while the third sample was negative, both by RT-PCR and FISH in the previous follow-up.
Samples analyzed during maintenance
Twenty-seven samples were analyzed by RT-PCR and FISH during maintenance, out of which four samples showed the presence of PML-RARA, both by RT-PCR and FISH, while the rest of the samples were negative by both the techniques.
Significance of RT-PCR and FISH results in monitoring MRD
We tried to correlate the results of RT-PCR and FISH to find out their significance in the monitoring of MRD in APL patients. It was seen that all the cases that were negative by RT-PCR and FISH at end of induction and consolidation, continued to remain in molecular remission with a median follow-up of 18 months.. There were four patients (cases 1 to 4, [Table 4]) who were positive both by RT-PCR and FISH at the end of induction, out of which two patients did not achieve molecular remission, while two patients were lost to follow-up. Out of the two patients who did not achieve molecular remission, one patient is alive while the other patient expired. There were three patients (cases 5 to 7) who were positive only by RT-PCR, but not by FISH. Out of these three patients, one patient did not achieve molecular remission and subsequently expired, even as the other two patients were in molecular remission, with a median follow-up of 16 months. There was one patient (case 8) who was negative by RT-PCR, but positive by FISH. This patient continues to be in molecular remission with a median follow-up of 12 months.
|Table 4 :Significance of transcriptase polymerase chain reaction and fluorescent in situ hybridization results|
Click here to view
Significance of MRD by RT-PCR and FISH at the end of induction
Out of the seven patients who were positive by RT-PCR at the end of induction, three patients relapsed, two were in remission, and two were lost to follow-up. The predictive value of relapse in the patients who were positive by RT-PCR at end of induction was 60 ± 11%. However, out of 33 patients who were negative at the end of induction by RT-PCR, only one patient relapsed, while all the rest continued to be in remission. The predictive value of relapse in the patients who were negative by RT-PCR at the end of induction was 3%. On the other hand, out of five patients who were positive by FISH at the end of induction, two patients relapsed, one patient was in remission, and two patients were lost to follow-up. Thus, the predictive value of relapse in the patients who were positive by FISH at the end of induction was 57 ± 13%. Out of 35 patients who were negative by FISH at the end of induction, two patients relapsed, while all the rest continued to be in remission. The predictive value of relapse in the patients who were negative by FISH at end of induction was 6%.
Significance of minimal residual disease by transcriptase polymerase chain reaction and fluorescent in situ hybridization at the end of consolidation
Out of the three patients who were positive by RT-PCR at end of consolidation, two patients relapsed while one patient was in remission. The predictive value of relapse in the patients who were positive by RT-PCR at the end of consolidation was 67%. Out of the other 23 patients who were negative by RT-PCR at end of consolidation, one patient relapsed, while all the rest were in molecular remission. Thus the predictive value of relapse in the patients who were negative by RT-PCR at the end of consolidation was 4%. On the other hand, all patients except one were negative by FISH at the end of consolidation. Out of these 22 patients, three patients relapsed, while all the rest were in remission. Thus, the predictive value of relapse in the patients who were negative by FISH at the end of consolidation was 14%.
| » Discussion|| |
Acute promyelocytic leukemia (APL or AML-M3) is a subtype of acute myeloid leukemia with distinct clinical and morphological features. Historically one of the most lethal forms of acute myeloid leukemia, APL leads to disseminated intravascular coagulation and death when not diagnosed and treated. Treatment with all-trans -retinoic acid substantially improves survival in patients who have failed anthracycline chemotherapy or for whom anthracycline is contraindicated. Similarly, arsenic trioxide is beneficial in APL patients who have failed or have contraindications for treatment with anthracycline or retinoid-based therapy. Genetically, APL is characterized by a unique chromosomal anomaly. More than 99% of the APL patients harbor a translocation between chromosomes 15 and 17, which fuse the retinoic acid receptor alpha (RARA) gene on chromosome 17 with the PML gene on chromosome 15. Detection of the PML-RARA t (15;17) translocation is diagnostic for APL, although the diagnosis can also be based on morphology. The presence of this translocation is necessary for response to the all-trans -retinoic acid and arsenic trioxide. Thus, the PML-RARA t (15;17) assay is useful for diagnosis and predicting treatment response. It is also helpful for monitoring the therapeutic response and MRD and for detecting early relapse. Both FISH and PCR methods may be used in the diagnosis of APL, to monitor patients for APL recurrence, and to predict a therapeutic response to all-trans -retinoic acid and arsenic trioxide therapies. The application of FISH not only allows to detect the reciprocal fusion of PML-RARA, but also the additional aberrations of 17q deletion, residual deletion of PML (unpublished data), and iso 17q.  These advantages of FISH technology at diagnosis are unique and cannot be detected by any other molecular technology including RT-PCR. Although, on the other hand, for suspected low-level, recurrent or MRD detection and monitoring, RT-PCR is recommended. The objective of this study is to compare and assess the role and sensitivity of FISH and RT-PCR in the diagnosis and monitoring of minimal residual disease in APL cases.
In the present study, the failure rate for RT-PCR at baseline was 4% and that for FISH was 8%.Out of the 52 samples received for RT-PCR, two samples had very faint RNA, which led to false negative results. In one of the studies conducted by S Iqbal et al. ,  out of the 28 APL cases, none were negative by RT-PCR, but three samples were negative by FISH, with a failure rate of 11%. Both the techniques had certain limitations in diagnosing APL. Absence of the t (15;17) by CK in APL cases most commonly reflected poor quality metaphases or cryptic rearrangements due to insertion events. FISH also failed to detect these cryptic insertions if locus-specific probes were not used. ,, however, these cryptic insertions could be easily detected by simple RT-PCR techniques. ,, According to most investigators, high-quality RNA and efficient RT were the crucial determinants for successful RT-PCR of PML-RARA ,, On account of frequent leukopenia and the associated coagulopathy, the yield and quality of RNA from diagnostic samples were frequently poor, and this led to failure and false negativity by RT-PCR. This required a repeat sample, which in turn added to the sample load of the laboratory and also caused inconvenience to the patient, as the patient had to undergo repeat bone marrow aspiration. In such cases, FISH on interphase nuclei was a reliable tool for the diagnosis of APL, with a sensitivity greater than that of FISH on metaphase cells and super imposable to that of RT-PCR. 
The presence of a specific and detectable tumor marker in leukemic cells allows investigators to molecularly assess the response to therapy and MRD in every patient with APL. Both FISH and RT-PCR are being used to molecularly monitor these patients. Although, a number of studies employing conventional PML-RARA assays, which typically detect up to one APL cell in 10 4 non-leukemic cells, have shown that extended courses of ATRA and combination chemotherapy ultimately induce PCR negativity in a vast majority of patients. ,,,,,
We analyzed the sensitivity of both these techniques for monitoring the minimal residual disease at the end of induction and consolidation. There have not been many studies, except for a few, , which have conducted a comparison between RT-PCR and FISH, to monitor MRD in APL patients. In one of the studies conducted by Mancini M et al. ,  11 patients who were investigated during complete remission (CR) by both FISH and RT-PCR, in order to evaluate residual disease; showed a very good correlation between RT-PCR and FISH. Although, in another study conducted by MLLF. Chauffaille,  of the six samples evaluated after treatment, the failure rate for FISH to detect residual disease was almost 50%. In the present study, discordance between RT-PCR and FISH was seen in four samples, at the end of induction. The failure rate for RT-PCR was 13% and that for FISH was 38%. Three samples were positive at the end of consolidation, with RT-PCR being positive in all the three cases, while FISH was positive in only two cases, with the failure rate being 66%. Four patients relapsed during maintenance; they were detected by both RT-PCR and FISH, which showed a good correlation Thus, it shows that the sensitivity of RT-PCR is more as compared to FISH, in detecting minimal residual disease up to the phase of consolidation, which is very critical for patient management and treatment. However, quality of the RNA has to be checked before, as this can lead to false negative results as seen in our study.
We further analyzed the significance of these MRD results obtained by both the techniques with respect to the remission status of the patients, in order to assess the false positive or negative results. It was seen that the predictive value of relapse in the patients who were positive by RT-PCR at end of induction was 60 ± 11%, and for those who were negative by RT-PCR, it was 3%. On the other hand the predictive value of relapse in the patients who were positive by FISH at end of induction was 57 ± 13%, and for those who were negative, it was 6%. Similarly, the predictive value of relapse in the patients who were positive by RT-PCR at end of consolidation was 67%, and for those who were negative, it was 4%. On the other hand the predictive value of relapse in the patients who were negative by FISH at the end of consolidation was 14%.
Till date there has not been any study that has compared both these techniques to assess the significance of MRD results obtained by both these techniques, with the remission status. The present study shows that the predictive value of relapse is associated more with the MRD results by RT-PCR than that by FISH.
Achievement of molecular remission is an important therapeutic goal in APL; as persistence of PML-RARA fusion transcripts until the end of chemotherapy consolidation, which occurs in 2 - 8% of the patients, ,,, has been found to be highly predictive of relapse,  which can, however, be averted by additional therapy such as allogenic BMT.  Even the present study shows that the positive results obtained by RT-PCR at the end of consolidation were more associated with relapse than with the results obtained at the end of induction, (60% at the end of induction, 67% at the end of consolidation). However, it was also seen that the some of the patients who were negative at the end of consolidation, eventually relapsed (predictive value being 4%). There have been studies that have shown that patients who are negative by RT-PCR ultimately go on to relapse. ,,,, This indicates that PCR assessment at this single time-point cannot be relied upon to determine the optimum treatment approach in individual patients. In the study reported by the GIMEMA group, which employed the AIDA protocol, no correlation was observed between the PCR status after induction and subsequent relapse risk.  This was consistent with the concept that detection of PML-RARA transcripts at this stage could very well relate to differentiating leukemic cells, subject to subsequent apoptosis, which could not be distinguished by conventional RT-PCR protocols from the residual APL blasts. In a recent study the Italian GIMEMA group reported that recurrence of PCR positivity detected by three monthly surveillance marrows performed after completion of therapy, was highly predictive of relapse.  By using such a strategy approximately 70% of the relapses were successfully predicted, with the majority (81%) of patients who ultimately relapsed converting to PCR positivity, within the first six months following completion of therapy. Median time from detection of molecular relapse to hematological relapse was three months, with a range of 1 - 14 months. However, for the MRC study in which the PCR status used PML-RARA and RARA-PML assays, it was determined after each course of chemotherapy, which suggested that the rate of clearance of disease-related transcripts was indeed an independent prognostic factor in APL. Detection of transcripts at any stage following induction or during consolidation therapy was associated with an increased risk of relapse. Therefore, while it was clear that reduction of PML-RARA transcripts to below the detectable threshold by standard RT-PCR assays (one in 10 4 ) was a prerequisite for long-term survival, and could currently represent our best therapeutic goal, achievement of PCR negativity could not be equated with cure.
The failure to detect residual disease in the marrow at the end of consolidation therapy in a significant proportion of patients, who ultimately relapsed, has highlighted the relative insensitivity of such assays, which has been ascribed to inefficiency of the RT step, and also to the relatively low expression of PML-RARA.  Indeed, analyses based on RNA derived from peripheral blood have been found to be even less sensitive,  thereby accounting for the reliance upon bone marrow sampling for MRD detection in this disease, to date. However, it also remains a possibility that in many cases, failure to detect residual disease is a reflection of sample quality giving rise to 'false-negative' results; while very occasionally MRD analyses performed on the marrow will fail to predict isolated extramedullary relapses.  In view of the relative insensitivity of the conventional nested PML-RARA RT-PCR assay, a number of different approaches such as, hotstart  PCR and real time PCR  have been used, to attempt to more accurately identify a subgroup of patients at a particularly high-risk of subsequent relapse. The cost of Real time PCR, although more sensitive than the conventional PCR, limits its usage for regular monitoring of APL patients. In order to circumvent this problem, we have been using the hotstart PCR along with recombinant Taq polymerase (HOTstar, Qiagen), which has increased the efficiency of RT-PCR and increased the sensitivity threshold of the detection of minimal residual in APL cases.
| » Conclusions|| |
Both RT-PCR and FISH are important for diagnosis of APL cases, as both the techniques complement each other in the absence or failure of any of them. In order to provide an accurate diagnosis, CK, FISH, and RT-PCR are mandatory in all newly suspected cases of APL. Despite its limitations, CK should continue to be used in diagnosis for the detection of karyotype patterns involving other chromosomes besides t (15;17). FISH offers some unique advantages over RT-PCR, where a single probe covers multiple dispersed breakpoints in chromosomal regions and can detect additional aberrations. Although we do not know the clinical significance of these aberrations, the long-term follow-up of such cases, in a large series, will help focus their clinical significance. Also with the use of cosmid probes, rare events of cryptic translocations can also be detected, which otherwise might be missed by normal probes, but can be detected by RT-PCR. RT-PCR is more sensitive than FISH for the detection of minimal residual disease, in long-term monitoring of these patients. Also, the results of the predictive value of relapse correlate more with RT-PCR than FISH. However, further investigation is needed to better establish the clinical value of molecular monitoring. In particular, the following have to be clarified: (1) whether a greater sensitivity of the RT-PCR assay for PML-RARA will allow better identification of patients at risk of relapse at the end of consolidation; (2) if newer quantitative technologies may provide earlier monitoring that is clinically significant; and (3) whether anticipation of salvage therapy in patients treated for molecular recurrence is more advantageous than the treatment of a hematological relapse. As to this latter issue, studies are underway,  but it may be anticipated that the therapy of molecular relapse can at least minimize the significant mortality rate observed during re-induction of overt disease.
| » References|| |
|1.||Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent change in acute promyelocytic leukaemia (letter). Lancet 1977;1:549-50. |
|2.||Lo Coco F, Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia 1998;12:1866-80. |
|3.||Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, et al. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 1997;90:4876-85. |
|4.||Miller WH, Kakizuka A, Frankel SR, Warrell RP, DeBlasio A Jr, Levine K, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992;89:2694-98. |
|5.||Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. New Engl J Med 1997;337:1021-28. |
|6.||Larson RA, Kondo K, Vardiman JW, Butler AE, Harvey, Golomb HM, Rowley JD, et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984;76:827-41. |
|7.||Zhang XX, Robinson LJ, Stenzel TT, Qumsiyeh MB. Translocation (15; 17) (q22; q21) as a Secondary Chromosomal Abnormality in a Case of Acute Monoblastic Leukemia with Tetrasomy 8 - treatment and prognosis in 99 cases. Can Gen Cyto 1999;113:9-13. |
|8.||Leea GY, Christinaa S, Tiena SL Abdul Ghafar AB, Hwang W, Lim LC, et al. Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia. Can Gen Cyto 2005;159:129-36. |
|9.||Saitoha K, Miuraa I, Kobayashia Y Kume M, Utsumi S, Takahashi N, et al. A New Variant Translocation of t(15;17) in a Patient with Acute Promyelocytic Leukemia (M3): t(15;19;17)(q22;p13;q12). Can Gen Cyto 1998;102:15-18. |
|10.||Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, et al. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immuno- fluorescence assessment of patients entered into the M.R.C. ATRA trial. Br J Haematol 1996;94:557-73. |
|11.||Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans-retinoic acid: result of the randomized MRC trial. Blood 1999;93:4131-43. |
|12.||Mancini M, Nanni M, Cedrone M, Diverioa D, Avvisati G, Riccioni R. Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission. Br J Haematol 1995;91:878-84. |
|13.||Schad CR, Hanson CA, Paietta E, Caasper J, Jalal SM, Dewald GW. Efficacy of fluorescence in situ hybridisation for detecting PML-RARA gene fusion in treated and untreated acute promyelocytic leukemia. Mayo Clin Proc 1994;69:1047-53. |
|14.||Fukutani H, Naoe T, Ohno R, Yoshida H, Kiyoi H, Miyawaki S, et al. Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. Leukemia 1995;9:588-93. |
|15.||Warrell RP, Barret AJ, Pandolfi PP, Willman CL. Acute myelocytic leukemia. 1999 Education Program, Am Soc Hemato 1997:120-137. |
|16.||Tobal K, JA Liu Yin. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long term remission of APL. Leukemia 1998;12:1349-54. |
|17.||Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, High- sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA 1986;83:2934-8. |
|18.||Amare PS, Baisane C, Saikia T, Nair R, Gawade H, Advani S. FISH, a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias. Can Gen Cyto 2001;131:125-34. |
|19.||Iqbal S, Grimwade D, Chase A, Goldstone AH, Burnett AK, Goldman JM, et al. Identification of PML-RARA rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients. Correspon Leuk 2000;14:950-53. |
|20.||Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies". Blood 2000;96:1297-308. |
|21.||Choughule A, Polampalli S, Amre P, Shinde S, Banavali SD, Kumar P, et al. Identification of PML/RARa fusion gene transcripts that showed no t(15;17) with conventional karyotyping and fluorescent in situ hybridization. Genet Mol Res 2009;8:1-7. |
|22.||Seale JRC, Varma S, Swirsky DM, Pandolfi PP, Goldman JM, Cross NCP. Quantification of PML/RARa transcripts in acute promyelocytic leukemia: Explanation for lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukemia specific mRNA by alpha interferon. Br J Haematol 1996;95:95-101. |
|23.||Diverio D, Riccioni R, Pistilli A, Buffolino S, Avvisati G, Mandelli F, et al. Improved rapid detection of the PML-RARa fusion gene in acute promyelocytic leukemia. Leukemia 1996;10:1214-16. |
|24.||Mancini M, Nanni M, Cedrone M, Diverio D, Avvisati G, Riccioni R, et al. Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission. Br J Haematol 1995;91:878-84. |
|25.||Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell Jr RP, Miller WH Jr, et al. Prognostic significance of minimal residual disease detection and PML/RAR_ isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001;98:2651-56. |
|26.||Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, et al. Molecular remission in PML/RARa positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-21. |
|27.||Miller WH, Levine K, De Blasio A, Frankel SR, Dmitrovsky E, Warrel RP Jr. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993;82:1689-94. |
|28.||Fukutani H, Naoe T, Ohno R, Yoshida H, Miyawaki S, Shimazaki C, et al. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. Leukemia 1995;9:1478-82. |
|29.||Gameiro P, Vieira S, Currara P, Silva AL, Diamond J, de Souza AB, et al. The PML-RAR_ transcript in long-term follow up of acute promyelocytic leukemia patients. Haematologica 2001;86:577-85. |
|30.||Chauffaille MLLF, Figueiredo MS, R. Beltrani, Antunes SV, Yamamoto M, Kerbauy J. Acute promyelocytic leukemia: the study of t(15;17) translocation by fluorescent in situ hybridization, reverse transcriptase-polymerase chain reaction and cytogenetic techniques. Braz J Med Biol Res 2001;34:735-43. |
|31.||Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa positive acute promyelocytic leukemia. Blood 1999;94:3015-21. |
|32.||Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia 2000;14:1362-70. |
|33.||Diverio D, Rossi V, Avvisati G, DeSantis S, Pistilli A, Pane F, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. Blood 1998;92:784-89. |
|34.||Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, et al. Molecular evaluation residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992;340:1437-38. |
|35.||Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E. Minimal residual disease detection in acute promyelocytic leukemia by reverse transcriptase PCR: evaluation of PMLRARa and RARa PML assessment in patients who ultimately relapse. Leukemia 1996;10:61-66. |
|36.||Devaraj PE, Foroni L, Prentice HG, Hoffbrand VA, Secker-Walker LM. Relapse of acute promyelocytic leukemia follows serial negative RT-PCR assays: a cautionary tale. Leukemia Research 1996;20:733-37. |
|37.||Tobal K, Moore H, Macheta M, Liu Yin JA. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARa transcripts with a sensitive competitive RT-PCR method. Leukemia 2001;15:1060-65. |
|38.||Lo Coco F, Diverio D, Petti MC, Avvisati G, Pogliani EM, Biondi A, et al. Therapy of minimal disease recurrence in acute promyelocytic leukemia. Br J Haematol 1998;102:149. |
[Table 1], [Table 2], [Table 3], [Table 4]
|This article has been cited by|
||Molecular biomarkers in acute myeloid leukemia
| ||Jeanette Prada-Arismendy,Johanna C. Arroyave,Sarah Röthlisberger |
| ||Blood Reviews. 2017; 31(1): 63 |
|[Pubmed] | [DOI]|
||Cytogenetic Profile of De Novo B lineage Acute Lymphoblastic Leukemia: Determination of Frequency, Distribution Pattern and Identification of Rare and Novel Chromosomal Aberrations in Indian Patients
| ||Prerana Bhandari,Firoz Ahmad,Rupa Dalvi,Neeraja Koppaka,Prajakta Kokate,Bibhu Ranjan Das,Swarna Mandava |
| ||Asian Pacific Journal of Cancer Prevention. 2015; 16(16): 7219 |
|[Pubmed] | [DOI]|
||Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013
| ||Katia Borgia Barbosa Pagnano,Eduardo Magalhães Rego,Sandra Rohr,Maria de Lourdes Chauffaille,Rafael Henriques Jacomo,Rosane Bittencourt,Ana Beatriz Firmato,Evandro Maranhão Fagundes,Raul Antonio Moraes Melo,Wanderley Bernardo |
| ||Revista Brasileira de Hematologia e Hemoterapia. 2014; 36(1): 71 |
|[Pubmed] | [DOI]|
||Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia
| || Authors of Document Ganzel, C., Douer, D., Tallman, M.S. |
| ||JNCCN Journal of the National Comprehensive Cancer Network. 2013; |
|| result 2 Document Molecular characteristics and clinical significance of 41 patients with acute promyelocytic leukemia
| || Cheng, H., Qiu, H.-Y., Gao, L., (...), Xu, Y.-Q., Wang, J.-M. |
| ||Source of the Document Journal of Leukemia and Lymphoma. 2013; |
||Expression of EBV Encoded viral RNA 1, 2 and anti-inflammatory Cytokine (interleukin-10) in FFPE lymphoma specimens: a preliminary study for diagnostic implication in Pakistan
| ||Taimoor I Sheikh,Ishtiaq Qadri |
| ||Diagnostic Pathology. 2011; 6(1): 70 |
|[Pubmed] | [DOI]|